|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM352126698 |
| 003 |
DE-627 |
| 005 |
20240202231925.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109243
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1278.xml
|
| 035 |
|
|
|a (DE-627)NLM352126698
|
| 035 |
|
|
|a (NLM)36702181
|
| 035 |
|
|
|a (PII)S1521-6616(23)00022-0
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Bagavant, Harini
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Anti-vimentin antibodies are associated with higher severity of Sjögren's disease
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 14.02.2023
|
| 500 |
|
|
|a Date Revised 02.02.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Vimentin is a ubiquitously present Type III intermediate filament protein, often targeted by autoimmune responses in multiple rheumatic disorders. Although previous studies have reported anti-vimentin antibodies in Sjögren's disease (SjD) patients, the clinical significance of such antibodies is unknown. To address this issue, the presence of anti-vimentin antibodies was determined in serum samples from a well-characterized cohort of primary SjD patients, non-SjD Sicca, and healthy controls. The occurrence of anti-vimentin antibodies and their association with different clinical features of the disease were evaluated. Anti-vimentin antibodies were detected in 24% of primary SjD patients, compared to 4% in non-SjD sicca patients and 3% in healthy controls. In primary SjD patients, higher levels of anti-vimentin antibodies were significantly associated with reduced saliva and tear flow and severe ocular surface damage indicators. The anti-vimentin antibody levels did not show significant associations with the presence or absence of other autoantibodies like ANA, RF, and anti-Ro/La. Our data suggest that the anti-vimentin antibody specificity arises in a subset of primary SjD patients and is associated with oral and ocular features of the disease. Anti-vimentin can potentially serve as a novel biomarker for evaluating the severity of salivary and lacrimal gland dysfunction in primary SjD
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Autoantibody
|
| 650 |
|
4 |
|a Cornea
|
| 650 |
|
4 |
|a Saliva
|
| 650 |
|
4 |
|a Sjögren's disease
|
| 650 |
|
4 |
|a Tears
|
| 650 |
|
4 |
|a Vimentin
|
| 650 |
|
7 |
|a Antibodies, Antinuclear
|2 NLM
|
| 650 |
|
7 |
|a Autoantibodies
|2 NLM
|
| 650 |
|
7 |
|a Biomarkers
|2 NLM
|
| 650 |
|
7 |
|a Vimentin
|2 NLM
|
| 700 |
1 |
|
|a Araszkiewicz, Antonina M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rasmussen, Astrid
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pezant, Nathan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Montgomery, Courtney
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Scofield, Robert Hal
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Farris, Darise
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lessard, Christopher J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Deshmukh, Umesh S
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 247(2023) vom: 01. Feb., Seite 109243
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:247
|g year:2023
|g day:01
|g month:02
|g pages:109243
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109243
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 247
|j 2023
|b 01
|c 02
|h 109243
|